About this trial
Interventional, randomised, Phase 3 study
previously treated metastatic NSCLC with a KRAS G12C mutation.
Where’s this trial being run?
Beaumont Hospital and Tallaght University Hospital
Can I join this study / trial?
The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.
Why not Print this page and bring it with you. It will help your doctor and research team advise you.Print this page
For more detailed informationClick Here
A Randomized Phase 3 Study of MRTX849 Versus Docetaxel in Patients With Previously Treated Non-Small Cell Lung Cancer With KRAS G12C Mutation
|Principal Investigator:||Dr Jarushka Naidoo|
Mirati Therapeutics Inc.
Global: January 2021
|Global Recruitment Target:||340|
|Ireland Recruitment Target:||9|